More FDA Oversight Of DTC Ads May Be Needed To Curtail Misleading Claims, Study Argues
Executive Summary
Clearer US guidance on DTC TV advertising and stronger enforcement would help reduce misleading claims and encourage drug makers to include more qualitative benefit/risk information in ads, according to a new study from Yale University researchers published in the Journal of General Internal Medicine.
You may also be interested in...
Did Lilly’s Olympic Ads Test The Boundaries On Celebrity Endorsement?
Only one of the six Olympic athletes promoting Lilly’s drugs actually took the product themselves or had a family member that did. Trulicity and Emgality TV ads include disclaimers while Verzenio commercial in memory of volleyball player April Ross’ mother does not.
Did Lilly’s Olympic Ads Test The Boundaries On Celebrity Endorsement?
Only one of the six Olympic athletes promoting Lilly’s drugs actually took the product themselves or had a family member that did. Trulicity and Emgality TV ads include disclaimers while Verzenio commercial in memory of volleyball player April Ross’ mother does not.
Diabetes DTC Ads Stand Out For Off-Label Promotion, Study Finds
Drugs like Victoza, Farxiga, Jardiance, Trulicity, and Invokana were called out for promoting weight loss and blood pressure reduction by Yale University researchers in a new study published in the Journal of General Internal Medicine.